Axel Baumgarten, MD

Center for Infectious Diseases (zidp), Germany

Disclosure(s): AbbVie: Honoraria; Gilead Sciences: Honoraria; Janssen: Honoraria; MSD: Honoraria; ViiV: Honoraria

Poster(s):

• 1251 - 5-year outcomes of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 count in two Phase 3 randomized clinical trials
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET